Coronavirus vaccine update: After working out the Pfizer coronavirus vaccine, US is now looking to pass the Moderna vaccine as well as coronavirus cases surge in the nation. A consultative panel of the US drug regulator has recommended the Moderna vaccine.
Meantime in India, AIIMS-Delhi is reportedly getting it hard to get enough participants for the Phase 3 trials of Covaxin, a Covid-19 vaccine candidate being produced by Hyderabad-based Bharat Biotech.
US FDA panel endorses Moderna vaccine
With the United States fighting another surge in Covid-19 cases and the population seeing another 2,32,255 fresh coronavirus cases on Wednesday. The nation is on the path to allow a second coronavirus vaccine after it started the rollout of the Pfizer vaccine last week.
US governors are now weighing in whether to allow emergency use sanction for the coronavirus vaccine developed by Moderna Inc. Just a week later an earlier vaccine from Pfizer Inc and German partner BioNTech SE won permission for mass distribution.
A panel of external advisers to the US Food and Drug Administration overwhelmingly confirmed Moderna’s vaccine candidate for emergency use after a daylong meeting on Thursday.
2 doses of Oxford vaccine show response
Early data from the trials of the coronavirus vaccine hopeful being developed by Oxford University and AstraZeneca present two full doses of the vaccine give a better immune response than the earlier tried one full dose and a half-dose booster.
Developers of the vaccine candidate have already announced late-stage test results determining higher efficiency when a half dose is followed by a full dose, compared to a two full-dose regime.
However, the newest details from the Phase I and 2 clinical trials published on Thursday made no mention of the half-dose/full-dose regime, which Oxford has said had been “unplanned” but approved by governors.
AIIMS unable to find volunteers
AIIMS-Delhi is reportedly incapable to find enough volunteers for the Phase 3 trials of Covaxin. A coronavirus vaccine candidate being produced by Bharat Biotech and ICMR. AIIMS officials have perceived people are reluctant to participate in the trials thinking a vaccine would anyway be available soon.
The All India Institute of Medical Sciences (AIIMS) in Delhi is one of the places conducting the final phase of the trial of Covid Vaccine and it requires around 1,500 volunteers.
“We needed 1,500-2,000 volunteers but so far, we have been able to recruit only around 200 volunteers. People are reluctant to participate in the activity thinking why to take part in a trial when a vaccine would be available soon for everyone,” Dr. Sanjay Rai, professor at AIIMS and also the principal researcher of the study, said.